Effect of clofibrate on the growth-kinetics of the murine P 1798(sc) lymphoma.
Clofibrate (CPIB) is a drug applied as an antilipidaemic agent in mammals. In this work we have tested its efficacy in vivo on the growth kinetics of P 1798(sc) lymphoma transplanted to recipient (BALB/c x AKR)F1 mice. Our results show a facilitation of the tumour growth rate in treated recipients. This fact may be related to an effect of the agent on the recipient which produces a decrease in the immune response as was confirmed on testing CPIB on thymus-dependent antigens in haemolytic plaque assays.
D000818:Animals; D002460:Cell Line; D002994:Clofibrate / Q000494:pharmacology*; D006462:Hemolytic Plaque Technique; D007165:Immunosuppression Therapy; D007700:Kinetics; D008055:Lipids / Q000097:blood; D008223:Lymphoma / Q000097:blood / Q000276:immunology / Q000473:pathology*; D051379:Mice; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000097:blood / Q000276:immunology / Q000473:pathology
D008055:Lipids; D002994:Clofibrate